Patient Focus: Novo Nordisk’s Way of Going From Talk to Walk

Primary tabs

Patient Focus: Novo Nordisk’s Way of Going From Talk to Walk

tweet me:
Novo Nordisk shares how pharma can put people @ centre of care. Peek in their new #TBL Quarterly #diabetes #WDC2015

Multimedia from this Release


A common business saying is that ‘the customer is always right’. But how do you involve the end customer - which for pharmaceutical companies means the patient - in an industry characterised by complex product development, diverse healthcare systems and long distribution chains? Novo Nordisk’s latest issue of TBL Quarterly shows how the company takes a collaborative approach with a long-term focus. 

Thursday, December 3, 2015 - 11:00am

CONTENT: Press Release

December 3, 2015 /3BL Media/ – Today, Novo Nordisk published a new issue of the company’s sustainability magazine, TBL Quarterly. The new issue – Patient focus: A snapshot of why we are in business – shows the value of dialogue and including the voice of people with diabetes and other chronic conditions in business decisions.

In the new issue, Novo Nordisk interviews people with type 1 and type 2 diabetes, healthcare professionals and employees to better understand the impact chronic conditions have on health, daily life, work, family relationships and emotional wellbeing.

Does patient focus mean dialogue-based doctor visits, personalised health planning and support, interactive electronic health records, new clinical trial designs? Download the new issue and discover where the next steps could be.

Download the new issue – ‘Patient focus: A snapshot of why we are in business’

The TBL Quarterly is published four times a year. If you want to receive notification when new issues are available, send a mail to

About the TBL Quarterly

Novo Nordisk manages its business in accordance with the Triple Bottom Line (TBL) business principle and pursues business solutions that maximise value to both the company and its stakeholders. Through selected themes, new perspectives and personal stories, the TBL Quarterly demonstrates how our TBL business principle supports long-term value creation. The TBL Quarterly is available as a reader-friendly PDF.

Explore previous issues of the TBL Quarterly

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions.

For more information, visit

Keywords: Health | Novo Nordisk | TBL | TBL quarterly | diabetes | patient focus | sustainability

CONTENT: Press Release